Tyra Biosciences (NASDAQ:TYRA) Price Target Increased to $30.00 by Analysts at HC Wainwright

Tyra Biosciences (NASDAQ:TYRA) had its price objective hoisted by HC Wainwright from $25.00 to $30.00 in a research report sent to investors on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

TYRA has been the topic of several other research reports. Piper Sandler started coverage on shares of Tyra Biosciences in a report on Thursday, August 15th. They issued an overweight rating and a $33.00 target price on the stock. Oppenheimer raised their price target on Tyra Biosciences from $25.00 to $33.00 and gave the company an outperform rating in a research note on Thursday, September 19th. Finally, Wedbush reiterated an outperform rating and issued a $28.00 price objective on shares of Tyra Biosciences in a report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of Moderate Buy and an average price target of $27.80.

Tyra Biosciences Stock Down 1.5 %

NASDAQ:TYRA opened at $20.98 on Monday. The stock’s fifty day moving average is $21.77 and its two-hundred day moving average is $19.15. Tyra Biosciences has a 52 week low of $10.38 and a 52 week high of $25.14. The company has a market capitalization of $1.11 billion, a P/E ratio of -12.49 and a beta of 1.01.

Tyra Biosciences (NASDAQ:TYRA) last released its earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09. Sell-side analysts anticipate that Tyra Biosciences will post -1.53 earnings per share for the current fiscal year.

Insider Buying and Selling at Tyra Biosciences

In related news, CEO Todd Harris sold 10,092 shares of the company’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $24.13, for a total value of $243,519.96. Following the completion of the sale, the chief executive officer now directly owns 1,479,528 shares of the company’s stock, valued at $35,701,010.64. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 16,890 shares of company stock worth $408,444 over the last 90 days. Corporate insiders own 15.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. RA Capital Management L.P. grew its holdings in shares of Tyra Biosciences by 43.9% during the first quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock worth $170,832,000 after buying an additional 3,180,155 shares during the last quarter. BVF Inc. IL lifted its holdings in shares of Tyra Biosciences by 70.1% during the first quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock worth $76,444,000 after purchasing an additional 1,921,599 shares during the period. Perceptive Advisors LLC grew its position in Tyra Biosciences by 50.5% in the 2nd quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock valued at $16,108,000 after buying an additional 338,208 shares during the last quarter. Vanguard Group Inc. raised its position in Tyra Biosciences by 18.6% during the 1st quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock worth $14,757,000 after buying an additional 140,833 shares during the last quarter. Finally, Kynam Capital Management LP lifted its stake in shares of Tyra Biosciences by 51.4% in the 1st quarter. Kynam Capital Management LP now owns 515,190 shares of the company’s stock worth $8,449,000 after acquiring an additional 175,000 shares during the period. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.